Tumour progression and metastasis are strongly associated with TAK1 (transforming growth factor β‐activated kinase 1) activity, and TAK1 deficiency leads to the deactivation of NF‐κB subunit p65, resulting in enhanced chemosensitivity in HCC cells and reduced tumourigenesis in lung cancer.8, 9. Here, NFKB1 is linked to lung carcinoma.